|
81
|
270
|
6bl8A |
Predicting the conformational variability of abl tyrosine kinase using molecular dynamics simulations and markov state models |
|
91
|
272
|
6brwA |
Jak2 jh2 in complex with xmu-mp-1 |
|
88
|
288
|
6bbuA |
Crystal structure of jak1 in complex with compound 25 |
|
127
|
417
|
6bhcA |
Crystal structure of pseduokinase peak1 (sugen kinase 269) |
|
98
|
289
|
6bbvA |
Crystal structure of jak2 in complex with compound 25 |
|
80
|
261
|
5zz4A |
Crystal structure of bruton's tyrosine kinase in complex with inhibitor 2e |
|
48
|
255
|
6amwA |
Abl1b regulatory module 'activating' conformation |
|
93
|
265
|
6auaA |
Crystal structure of bruton's tyrosine kinase in complex with inhibitor cgi2625 |
|
78
|
273
|
5zxbA |
Crystal structure of ack1 with compound 10d |
|
58
|
255
|
6amvA |
Abl 1b regulatory module 'inhibiting state' |
|
89
|
264
|
6aubA |
Crystal structure of bruton's tyrosine kinase in complex with inhibitor cgi2815 |
|
90
|
271
|
5zj6A |
Crystal structure of hck kinase complexed with a pyrrolo-pyrimidine inhibitor 7-[trans-4-(4-methylpiperazin-1-yl)cyclohexyl]-5-(4-phenoxyphenyl)-7h-pyrrolo[2,3-d]pyrimidin-4-amine |
|
87
|
273
|
5y5tA |
Crystal structures of spleen tyrosine kinase in complex with a novel inhibitor |
|
87
|
271
|
5y5uA |
Crystal structures of spleen tyrosine kinase in complex with a novel inhibitor |
|
82
|
274
|
5wijA |
Jak2 pseudokinase in complex with nu6140 |
|
87
|
283
|
5wfjA |
The jak3 kinase domain in complex with a covalent inhibitor |
|
81
|
274
|
5wilA |
Jak2 pseudokinase in complex with azd7762 |
|
78
|
278
|
5vc3A |
Crystal structure of human wee1 kinase domain in complex with bosutinib |
|
78
|
306
|
5w5oA |
Identification of potent and selective ripk2 inhibitors for the treatment of inflammatory diseases. |
|
78
|
274
|
5wikB |
Jak2 pseudokinase in complex with bi-d1870 |
|
94
|
271
|
5vfiA |
Bruton's tyrosine kinase (btk) with gdc-0853 |
|
93
|
275
|
5cxzA |
Syk catalytic domain complexed with naphthyridine inhibitor |
|
97
|
292
|
5cf8A |
Crystal structure of janus kinase 2 in complex with n,n-dicyclopropyl-10-ethyl-7-[(3-methoxypropyl)amino] -3-methyl-3,5,8,10-tetraazatricyclo[7.3.0.0,6] dodeca-1(9),2(6),4,7,11-pentaene-11-carboxamide |
|
94
|
290
|
5cf6A |
Crystal structure of janus kinase 2 in complex with n,n-dicyclopropyl-10-[(2s)-2,3-dihydroxypropyl]-3-methyl-7-(methylamino)-3,5,8,10-tetraazatricyclo [7.3.0.02,6]dodeca-1(9),2(6),4,7,11-pentaene-11-carboxamide |
|
98
|
292
|
5cf5A |
Crystal structure of janus kinase 2 in complex with n,n-dicyclopropyl-7-[(dimethyl-1,3-thiazol-2-yl)amino]-10-ethyl-3-methyl-3,5,8,10-tetraazatricyclo[7.3.0.02,6] dodeca-1(9),2(6),4,7,11-pentaene-11-carboxamide |
|
93
|
289
|
5cf4A |
Crystal structure of janus kinase 2 in complex with n,n-dicyclopropyl-10-ethyl-7-[(3-methoxypropyl)amino] -3-methyl-3,5,8,10-tetraazatricyclo[7.3.0.0,6] dodeca-1(9),2(6),4,7,11-pentaene-11-carboxamide |
|
93
|
274
|
5c26A |
Crystal structure of syk in complex with compound 1 |
|
89
|
271
|
5bq0A |
Crystal structure of bruton agammaglobulinemia tyrosine kinase complexed with bms-824171 aka 6-[(3r)-3-(4-tert-bu tylbenzamido)piperidin-1-yl]-2-{[4-(morpholine-4-carbonyl) phenyl]amino}pyridine-3-carboxamide |
|
89
|
263
|
5bpyA |
Crystal structure of bruton agammaglobulinemia tyrosine kinase complexed with bms-824171 aka 6-[(3r)-3-(4-tert-bu tylbenzamido)piperidin-1-yl]-2-{[4-(morpholine-4-carbonyl) phenyl]amino}pyridine-3-carboxamide |
|
99
|
292
|
5aepA |
Novel pyrrole carboxamide inhibitors of jak2 as potential treatment of myeloproliferative disorders |
|
86
|
290
|
4hvgA |
Jak3 kinase domain in complex with 2-cyclopropyl-5h-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((s)-2-hydroxy-1,2-dimethyl-propyl)-amide |
|
90
|
270
|
4zlzA |
Crystal structure of bruton's tyrosine kinase in complex with a substituted cinnoline |
|
89
|
270
|
4zlyA |
Crystal structure of bruton's tyrosine kinase bound to a cinnoline fragment |
|
85
|
290
|
4z16A |
Crystal structure of the jak3 kinase domain covalently bound to n-(3-(((5-chloro-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)methyl)phenyl)acrylamide |
|
99
|
289
|
4ytfA |
Discovery of vx-509 (decernotinib): a potent and selective janus kinase (jak) 3 inhibitor for the treatment of autoimmune diseases |
|
98
|
289
|
4ytcA |
Discovery of vx-509 (decernotinib): a potent and selective janus kinase (jak) 3 inhibitor for the treatment of autoimmune disease |
|
124
|
478
|
4z32A |
Crystal structure of the ferm-sh2 domains of jak2 |
|
93
|
271
|
4z3vA |
Fragment-based discovery of a small molecule reversible inhibitor of bruton's tyrosine kinase |
|
98
|
328
|
4umrA |
Structure of melk in complex with inhibitors |
|
97
|
333
|
4umpA |
Structure of melk in complex with inhibitors |
|
107
|
331
|
4umuA |
Structure of melk in complex with inhibitors |
|
96
|
265
|
4rx5A |
Bruton's tyrosine kinase (btk) with pyridazinone compound 23 |
|
28
|
108
|
4f5bA |
Triple mutant src sh2 domain bound to phosphotyrosine |
|
29
|
108
|
4f59A |
Triple mutant src sh2 domain |
|
84
|
273
|
4f4pA |
Syk in complex with ligand lasw836 |
|
91
|
290
|
4f08A |
Discovery and optimization of c-2 methyl imidazo-pyrrolopyridines as potent and orally bioavailable jak1 inhibitors with selectivity over jak2 |
|
82
|
287
|
4hviA |
Jak3 kinase domain in complex with 2-cyclopropyl-5h-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((r)-1-methyl-2-oxo-2-piperidin-1-yl-ethyl)-amide |
|
28
|
108
|
4f5aA |
Triple mutant src sh2 domain bound to phosphate ion |
|
78
|
275
|
4ewhA |
Co-crystal structure of ack1 with inhibitor |
|
83
|
287
|
4hvdA |
Jak3 kinase domain in complex with 2-cyclopropyl-5h-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((s)-1,2,2-trimethyl-propyl)-amide |
